Peptide YY3-36 oral - Emisphere Technologies

Drug Profile

Peptide YY3-36 oral - Emisphere Technologies

Alternative Names: PYY3-36

Latest Information Update: 03 Jun 2009

Price : $50

At a glance

  • Originator Emisphere Technologies
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Neuropeptide Y2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 27 May 2009 Final efficacy data from a phase 1 trial in normal weight males released by Emisphere
  • 02 Apr 2007 Clinical data added to the pharmacokinetics and Obesity pharmacodynamics sections
  • 29 Mar 2007 Phase-I clinical trials in Obesity in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top